- Home
- ARCL vs LYEL Comparison
ARCL vs LYEL Comparison
Compare ARCL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARCL | LYEL |
|---|---|---|
| Founded | 2025 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.4M | 195.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARCL | LYEL |
|---|---|---|
| Price | $10.01 | $9.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $37.88 |
| AVG Volume (30 Days) | 34.9K | ★ 149.4K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.88 | $7.20 |
| 52 Week High | $10.03 | $45.00 |
Technical Indicators
Market Signals| Indicator | ARCL | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 35.71 |
| Support Level | $9.96 | N/A |
| Resistance Level | $10.02 | $15.38 |
| Average True Range (ATR) | 0.01 | 0.62 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 72.73 | 48.31 |
Price Performance
Historical ComparisonAbout ARCL ARC Group Acquisition I Corp Class A Ordinary Shares
ARC Group Acquisition I Corp is a blank check company.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.